BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,563,864 | -24.7% | 37,665 | -9.7% | 0.00% | -20.0% |
| Q2 2023 | $3,404,323 | +19.2% | 41,704 | +8.3% | 0.01% | +25.0% |
| Q1 2023 | $2,856,489 | -3.3% | 38,502 | +8.0% | 0.00% | 0.0% |
| Q4 2022 | $2,953,532 | +30.0% | 35,636 | +345.3% | 0.00% | 0.0% |
| Q3 2022 | $2,272,000 | -45.8% | 8,003 | -33.8% | 0.00% | -42.9% |
| Q2 2022 | $4,189,000 | -21.6% | 12,085 | -2.1% | 0.01% | 0.0% |
| Q1 2022 | $5,345,000 | -20.5% | 12,342 | -5.0% | 0.01% | -22.2% |
| Q4 2021 | $6,722,000 | +0.8% | 12,994 | -5.6% | 0.01% | -10.0% |
| Q3 2021 | $6,668,000 | +8.0% | 13,761 | +0.4% | 0.01% | +11.1% |
| Q2 2021 | $6,172,000 | +17.4% | 13,707 | -0.4% | 0.01% | 0.0% |
| Q1 2021 | $5,256,000 | +27.0% | 13,763 | +5.6% | 0.01% | +28.6% |
| Q4 2020 | $4,139,000 | +43.6% | 13,032 | +12.0% | 0.01% | +16.7% |
| Q3 2020 | $2,882,000 | +2.6% | 11,635 | +9.4% | 0.01% | 0.0% |
| Q2 2020 | $2,809,000 | +37.3% | 10,637 | -1.4% | 0.01% | 0.0% |
| Q1 2020 | $2,046,000 | -8.9% | 10,790 | +5.4% | 0.01% | +20.0% |
| Q4 2019 | $2,247,000 | +23.1% | 10,235 | +9.9% | 0.01% | 0.0% |
| Q3 2019 | $1,825,000 | +4.9% | 9,315 | +11.6% | 0.01% | +25.0% |
| Q2 2019 | $1,740,000 | -18.3% | 8,346 | -22.3% | 0.00% | -33.3% |
| Q1 2019 | $2,131,000 | +46.6% | 10,739 | +6.7% | 0.01% | +20.0% |
| Q4 2018 | $1,454,000 | -33.4% | 10,069 | -6.0% | 0.01% | -16.7% |
| Q3 2018 | $2,183,000 | +56.2% | 10,707 | +13.4% | 0.01% | +50.0% |
| Q2 2018 | $1,398,000 | -6.2% | 9,443 | -4.4% | 0.00% | -20.0% |
| Q1 2018 | $1,491,000 | +22.0% | 9,877 | +4.8% | 0.01% | +25.0% |
| Q4 2017 | $1,222,000 | +10.7% | 9,429 | +3.1% | 0.00% | 0.0% |
| Q3 2017 | $1,104,000 | +3.0% | 9,145 | +0.5% | 0.00% | 0.0% |
| Q2 2017 | $1,072,000 | +18.1% | 9,103 | +2.0% | 0.00% | 0.0% |
| Q1 2017 | $908,000 | +10.5% | 8,928 | +11.4% | 0.00% | +33.3% |
| Q4 2016 | $822,000 | +138.3% | 8,015 | +155.5% | 0.00% | +50.0% |
| Q3 2016 | $345,000 | +16.6% | 3,137 | +19.4% | 0.00% | +100.0% |
| Q2 2016 | $296,000 | +24.4% | 2,628 | -0.8% | 0.00% | 0.0% |
| Q4 2015 | $238,000 | -11.2% | 2,649 | -9.1% | 0.00% | -50.0% |
| Q3 2015 | $268,000 | -50.0% | 2,913 | -46.5% | 0.00% | +100.0% |
| Q2 2015 | $536,000 | +94.2% | 5,448 | +98.0% | 0.00% | -50.0% |
| Q1 2015 | $276,000 | +10.0% | 2,751 | +1.2% | 0.00% | +100.0% |
| Q4 2014 | $251,000 | – | 2,718 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |